Teva Pharmaceutical IndustriesFRA:TEV 58 Shareholder Yield % is 3.00% as of Mar. 2026, which is 72% below its 10-year median of 10.88. GuruFocus rates FRA:TEV with a GF Score™ of 58/100 and a GF Value™ of €17.67 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 973 Drug Manufacturers companies, Teva Pharmaceutical Industries ranks better than 70.91% on this metric.
Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. It is a measure of shareholder return.
As of today, Teva Pharmaceutical Industries's Shareholder Yield % was 3.00%.
Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. The term was coined by William W. Priest of Epoch Investment Partners in a paper in 2005 entitled The Case for Shareholder Yield as a Dominant Driver of Future Equity Returns. William Priest indicated that "shareholder yield is a term that we came up with to reflect the various ways dividends can be paid to owners of a business in a publicly-traded company."
Dividend Yield % shows how much a company pays out in dividends each year relative to its stock price, which is most obvious form of shareholder return.
Buyback Yield % is the net repurchase of shares outstanding over the market capital of the company. Shares repurchases also increase shareholder value by returning the money back to shareholders.
Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced.
Teva Pharmaceutical Industries Shareholder Yield % Related Terms
Teva Pharmaceutical Industries Shareholder Yield % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:TEV vs ZTS, UTHR, VTRS: Shareholder Yield % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Teva Pharmaceutical Industries's Shareholder Yield %, along with its competitors' market caps and Shareholder Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Teva Pharmaceutical Industries Shareholder Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Teva Pharmaceutical Industries's Shareholder Yield % distribution charts can be found below:
* The bar in red indicates where Teva Pharmaceutical Industries's Shareholder Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Shareholder Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.
Teva Pharmaceutical Industries (FRA:TEV) has a Shareholder Yield % of 3.00% as of Mar. 2026. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on Teva Pharmaceutical Industries and its competitors. This is 72% below median its historical median of 10.88. According to the industry distribution chart, Teva Pharmaceutical Industries ranks #283 out of 973 companies in the Drug Manufacturers industry, placing it in the top 29.1%.
Is Teva Pharmaceutical Industries' Shareholder Yield % too high?
Teva Pharmaceutical Industries' current Shareholder Yield % of 3.00% is 72% below median its 10-year median of 10.88. The Drug Manufacturers industry median Shareholder Yield % is 0.31. Teva Pharmaceutical Industries' value of 3.00% is 867.7% above this industry median. Based on the distribution chart, Teva Pharmaceutical Industries ranks #283 out of 973 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Teva Pharmaceutical Industries has a GF Score™ of 58/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Teva Pharmaceutical Industries' Shareholder Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Teva Pharmaceutical Industries ranks #283 out of 973 companies for Shareholder Yield %. This puts Teva Pharmaceutical Industries in the upper half of its industry. The industry median Shareholder Yield % is 0.31. Teva Pharmaceutical Industries' value of 3.00% is 867.7% above this benchmark. While the company's 10-year median is 10.88 vs. the industry median of 0.31, Teva Pharmaceutical Industries has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shareholder Yield % for a Drug Manufacturers company?
The median Shareholder Yield % among Drug Manufacturers companies is 0.31, based on 973 companies in the industry. Companies in the top quartile (top 25%) have a Shareholder Yield % significantly above this median, while those in the bottom quartile fall well below. However, Shareholder Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Teva Pharmaceutical Industries's current Shareholder Yield % of 3.00% is 867.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shareholder Yield % mean?
A high Shareholder Yield % can signal that a stock is expensive relative to its fundamentals. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on Teva Pharmaceutical Industries and its competitors. For the Drug Manufacturers industry, the median Shareholder Yield % is 0.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Teva Pharmaceutical Industries's current Shareholder Yield % is 3.00%, which is 72% below median its own 10-year median of 10.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Teva Pharmaceutical Industries stock overvalued right now?
Based on GuruFocus' analysis, Teva Pharmaceutical Industries (FRA:TEV) is currently considered Significantly Overvalued. The stock's GF Value™ is €17.67, compared to a current price of €28.50 — trading 61.3% above its estimated fair value. The current Shareholder Yield % is 3.00%, which is 72% below median its 10-year median of 10.88 and 867.7% above the Drug Manufacturers industry median of 0.31. Teva Pharmaceutical Industries' overall GF Score™ is 58/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shareholder Yield % calculated?
Shareholder Yield % is calculated from a company's financial statements. For Teva Pharmaceutical Industries (FRA:TEV), the current Shareholder Yield % is 3.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Teva Pharmaceutical Industries (FRA:TEV) Overvalued in 2026?
Based on GuruFocus' analysis, Teva Pharmaceutical Industries stock appears to be overvalued.
The current stock price of €28.50 is trading 61.3% above its estimated GF Value™ of €17.67.
GuruFocus considers Teva Pharmaceutical Industries to be Significantly Overvalued.
Key valuation signals for FRA:TEV:
Shareholder Yield %: 3.00% (72% below median its 10-year median of 10.88)
GF Value™: €17.67 vs. price of €28.50 (61.3% above fair value)
Industry Position: 867.7% above the Drug Manufacturers median (#283 of 973)
No single metric tells the full story. See the FRA:TEV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Teva Pharmaceutical Industries Business Description
Teva Pharmaceutical, based in Israel, is the world's leading generic drug manufacturer. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in two main therapeutic areas: neurology and immunology. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
58GF Score
Get the complete analysis for FRA:TEV
Shareholder Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:TEV has been successfully added to your 
